(TLRY) Tilray - Overview
Stock: Cannabis, Beverage, Hemp, Wellness, Distribution
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 104% |
| Relative Tail Risk | -26.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | -51.39 |
| Character TTM | |
|---|---|
| Beta | 1.571 |
| Beta Downside | 2.018 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.12% |
| CAGR/Max DD | -0.40 |
Description: TLRY Tilray January 26, 2026
Tilray Brands, Inc. (NASDAQ:TLRY) is a diversified lifestyle consumer products company that cultivates, processes, and distributes medical and adult-use cannabis, hemp-based foods, and alcoholic-and-non-alcoholic beverages across North America, Europe, the Middle East, and Africa. The business is organized into four operating segments-Beverage, Cannabis, Distribution, and Wellness-and sells under a wide array of brands such as Tilray, Aphria, Charlotte’s Web, SweetWater Brewing, and Manitoba Harvest to retailers, wholesalers, physicians, hospitals, governments, and directly to consumers.
Key recent metrics (as of Q3 2025):
• Revenue reached $1.12 billion, up 12 % year-over-year, driven primarily by a 22 % increase in the Beverage segment’s hemp-infused drink sales.
• Adjusted EBITDA margin stood at 8 %, reflecting improved cost efficiencies after the 2022 merger integration.
• The global legal cannabis market is projected to grow at a 14 % compound annual growth rate through 2029, with U.S. federal legalization prospects remaining the most material upside catalyst for Tilray’s U.S. adult-use pipeline.
These figures come from Tilray’s latest Form 10-Q filing and Bloomberg consensus forecasts; however, they are subject to change pending regulatory developments and macro-economic volatility.
For a deeper dive into Tilray’s valuation dynamics, examine its recent cash-flow trends and comparable peer multiples.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -2.95b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -1.07 > 1.0 |
| NWC/Revenue: 56.21% < 20% (prev 52.90%; Δ 3.31% < -1%) |
| CFO/TA -0.01 > 3% & CFO -38.7m > Net Income -2.95b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.3m) vs 12m ago 27.57% < -2% |
| Gross Margin: 28.01% > 18% (prev 0.30%; Δ 2771 % > 0.5%) |
| Asset Turnover: 26.56% > 50% (prev 19.34%; Δ 7.23% > 0%) |
| Interest Coverage Ratio: -89.43 > 6 (EBITDA TTM -2.92b / Interest Expense TTM 34.2m) |
Altman Z'' -15.00
| A: 0.22 (Total Current Assets 1.02b - Total Current Liabilities 362.3m) / Total Assets 2.93b |
| B: -2.33 (Retained Earnings -6.83b / Total Assets 2.93b) |
| C: -0.70 (EBIT TTM -3.06b / Avg Total Assets 4.40b) |
| D: -8.93 (Book Value of Equity -6.89b / Total Liabilities 771.3m) |
| Altman-Z'' Score: -20.19 = D |
Beneish M -4.00
| DSRI: 0.94 (Receivables 152.4m/157.7m, Revenue 1.17b/1.13b) |
| GMI: 1.09 (GM 28.01% / 30.47%) |
| AQI: 0.55 (AQ_t 0.38 / AQ_t-1 0.69) |
| SGI: 1.03 (Revenue 1.17b / 1.13b) |
| TATA: -0.99 (NI -2.95b - CFO -38.7m) / TA 2.93b) |
| Beneish M-Score: -4.27 (Cap -4..+1) = AAA |
What is the price of TLRY shares?
Over the past week, the price has changed by +1.61%, over one month by -18.14%, over three months by -37.36% and over the past year by -28.49%.
Is TLRY a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TLRY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.8 | 56.1% |
| Analysts Target Price | 11.8 | 56.1% |
| ValueRay Target Price | 5.3 | -30.6% |
TLRY Fundamental Data Overview February 09, 2026
P/S = 1.038
P/B = 0.5619
Revenue TTM = 1.17b USD
EBIT TTM = -3.06b USD
EBITDA TTM = -2.92b USD
Long Term Debt = 225.0m USD (from longTermDebt, last quarter)
Short Term Debt = 46.0m USD (from shortTermDebt, last quarter)
Debt = 446.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 101.9m USD (from netDebt column, last quarter)
Enterprise Value = 908.4m USD (869.1m + Debt 446.5m - CCE 407.3m)
Interest Coverage Ratio = -89.43 (Ebit TTM -3.06b / Interest Expense TTM 34.2m)
EV/FCF = -9.61x (Enterprise Value 908.4m / FCF TTM -94.5m)
FCF Yield = -10.40% (FCF TTM -94.5m / Enterprise Value 908.4m)
FCF Margin = -8.09% (FCF TTM -94.5m / Revenue TTM 1.17b)
Net Margin = -252.6% (Net Income TTM -2.95b / Revenue TTM 1.17b)
Gross Margin = 28.01% ((Revenue TTM 1.17b - Cost of Revenue TTM 840.9m) / Revenue TTM)
Gross Margin QoQ = 26.43% (prev 27.43%)
Tobins Q-Ratio = 0.31 (Enterprise Value 908.4m / Total Assets 2.93b)
Interest Expense / Debt = 1.68% (Interest Expense 7.51m / Debt 446.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.42b (EBIT -3.06b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.81 (Total Current Assets 1.02b / Total Current Liabilities 362.3m)
Debt / Equity = 0.20 (Debt 446.5m / totalStockholderEquity, last quarter 2.21b)
Debt / EBITDA = -0.03 (negative EBITDA) (Net Debt 101.9m / EBITDA -2.92b)
Debt / FCF = -1.08 (negative FCF - burning cash) (Net Debt 101.9m / FCF TTM -94.5m)
Total Stockholder Equity = 2.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -67.09% (Net Income -2.95b / Total Assets 2.93b)
RoE = -114.1% (Net Income TTM -2.95b / Total Stockholder Equity 2.59b)
RoCE = -109.0% (out of range, set to none) (EBIT -3.06b / Capital Employed (Equity 2.59b + L.T.Debt 225.0m))
RoIC = -115.2% (out of range, set to none) (NOPAT -2.42b / Invested Capital 2.10b)
WACC = 8.18% (E(869.1m)/V(1.32b) * Re(11.70%) + D(446.5m)/V(1.32b) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 11.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.88%
Fair Price DCF = unknown (Cash Flow -94.5m)
EPS Correlation: 25.61 | EPS CAGR: -1.50% | SUE: -0.01 | # QB: 0
Revenue Correlation: 91.04 | Revenue CAGR: 12.85% | SUE: 0.80 | # QB: 0
EPS current Year (2026-05-31): EPS=0.02 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=-84.8% | Growth Revenue=+5.4%
EPS next Year (2027-05-31): EPS=-0.29 | Chg30d=-0.020 | Revisions Net=-1 | Growth EPS=+50.2% | Growth Revenue=+4.7%